Curanex Pharmaceuticals Inc (NASDAQ:CURX) Shares Shorted: Short Interest Up 68.5% in October

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 5,195 shares, a growth of 68.5% from the September 30th total of 3,084 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily trading volume, of 28,196 shares, the days-to-cover ratio is presently 0.2 days.

Curanex Pharmaceuticals Stock Performance

CURX opened at $6.19 on Wednesday. The firm’s fifty day moving average is $4.77 and its two-hundred day moving average is $6.15. The firm has a market cap of $9.72 million, a PE ratio of -0.79 and a beta of -2.99. Curanex Pharmaceuticals has a twelve month low of $3.58 and a twelve month high of $13.44.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Tuesday, October 27th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.